PALO ALTO, CA, USA I July 22, 2013 I Cellular Biomedicine Group (CBMG) today announced that it has completed the enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of the medical technology haMPC (Human Adipose-derived Mesenchymal Progenitor Cells) therapy for Knee Osteoarthritis (KOA).
“We are pleased that our patient enrollment is on schedule with our projected time to complete the Phase I clinical trial for Knee Osteoarthritis,” said Dr. Cheng Xiang (Chase) Dai, VP and GM of Autologous Products Business Unit.
The Phase I open label clinical research trial for KOA, registered with the U.S. National Institutes of Health (NIH) under number NCT01809769 (click here to view), tests the safety and efficacy of intra-articular injections of autologous (patient’s own) haMPC in order to reduce inflammation and regenerate damaged joint tissues. This trial is conducted at Shanghai Renji Hospital, one of the largest teaching hospitals in China. To date the trial has had no Severe Adverse Effect (SAE) reported.
Knee Osteoarthritis in China
There are approximately 57 million people in China suffering from knee osteoarthritis (source: International Journal of Rheumatic Diseases, 2011) As drug-based methods of management are ineffective, many patients with this disability will degenerate to the point of requiring artificial joint replacement surgery every year.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
SOURCE: Cellular Biomedicine
Post Views: 246
PALO ALTO, CA, USA I July 22, 2013 I Cellular Biomedicine Group (CBMG) today announced that it has completed the enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of the medical technology haMPC (Human Adipose-derived Mesenchymal Progenitor Cells) therapy for Knee Osteoarthritis (KOA).
“We are pleased that our patient enrollment is on schedule with our projected time to complete the Phase I clinical trial for Knee Osteoarthritis,” said Dr. Cheng Xiang (Chase) Dai, VP and GM of Autologous Products Business Unit.
The Phase I open label clinical research trial for KOA, registered with the U.S. National Institutes of Health (NIH) under number NCT01809769 (click here to view), tests the safety and efficacy of intra-articular injections of autologous (patient’s own) haMPC in order to reduce inflammation and regenerate damaged joint tissues. This trial is conducted at Shanghai Renji Hospital, one of the largest teaching hospitals in China. To date the trial has had no Severe Adverse Effect (SAE) reported.
Knee Osteoarthritis in China
There are approximately 57 million people in China suffering from knee osteoarthritis (source: International Journal of Rheumatic Diseases, 2011) As drug-based methods of management are ineffective, many patients with this disability will degenerate to the point of requiring artificial joint replacement surgery every year.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
SOURCE: Cellular Biomedicine
Post Views: 246
